1. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012 97:2272-82.
https://doi.org/10.1210/jc.2012-1027.
3. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005 90:1294-301.
https://doi.org/10.1210/jc.2004-0952.
4. Kim HY, Ha YC, Kim TY, et al. Healthcare costs of osteoporotic fracture in Korea: information from the national health insurance claims database, 2008-2011. J Bone Metab 2017 24:125-33.
https://doi.org/10.11005/jbm.2017.24.2.125.
6. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010 25:2267-94.
https://doi.org/10.1002/jbmr.253.
7. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014 29:1-23.
https://doi.org/10.1002/jbmr.1998.
9. LeBlanc ES, Rosales AG, Black DM, et al. Evaluating atypical features of femur fractures: how change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting. J Bone Miner Res 2017 32:2304-14.
https://doi.org/10.1002/jbmr.3221.
12. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012 27:2544-50.
https://doi.org/10.1002/jbmr.1719.
13. Mahjoub Z, Jean S, Leclerc JT, et al. Incidence and characteristics of atypical femoral fractures: clinical and geometrical data. J Bone Miner Res 2016 31:767-76.
https://doi.org/10.1002/jbmr.2748.
14. Lo JC, Hui RL, Grimsrud CD, et al. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 2016 85:142-7.
https://doi.org/10.1016/j.bone.2016.01.002.
18. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013 28:1729-37.
https://doi.org/10.1002/jbmr.1893.
19. Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 2020 383:743-53.
https://doi.org/10.1056/NEJMoa1916525.
20. Donnelly E, Meredith DS, Nguyen JT, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012 27:672-8.
https://doi.org/10.1002/jbmr.560.
21. Durchschlag E, Paschalis EP, Zoehrer R, et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006 21:1581-90.
https://doi.org/10.1359/jbmr.060701.
22. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001 28:524-31.
https://doi.org/10.1016/s8756-3282(01)00414-8.
23. Tjhia CK, Odvina CV, Rao DS, et al. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 2011 49:1279-89.
https://doi.org/10.1016/j.bone.2011.09.042.
25. Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013 98:4483-92.
https://doi.org/10.1210/jc.2013-1597.
26. Selga J, Nuñez JH, Minguell J, et al. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int 2016 27:827-32.
https://doi.org/10.1007/s00198-015-3355-z.
27. Haider IT, Schneider P, Michalski A, et al. Influence of geometry on proximal femoral shaft strains: implications for atypical femoral fracture. Bone 2018 110:295-303.
https://doi.org/10.1016/j.bone.2018.02.015.
28. Silverman S, Kupperman E, Bukata S. Bisphosphonate-related atypical femoral fracture: managing a rare but serious complication. Cleve Clin J Med 2018 85:885-93.
https://doi.org/10.3949/ccjm.85a.17119.
29. Marshall RA, Mandell JC, Weaver MJ, et al. Imaging features and management of stress, atypical, and pathologic fractures. Radiographics 2018 38:2173-92.
https://doi.org/10.1148/rg.2018180073.
30. Fang C, Chau JY, Woo SB, et al. Propagation of bisphosphonate-related femoral stress fractures despite femoral nailing: a cautionary tale from 2 cases. Geriatr Orthop Surg Rehabil 2014 5:14-7.
https://doi.org/10.1177/2151458514522058.
31. van de Laarschot DM, Smits AA, Buitendijk SK, et al. Screening for atypical femur fractures using extended femur scans by DXA. J Bone Miner Res 2017 32:1632-9.
https://doi.org/10.1002/jbmr.3164.
32. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016 31:16-35.
https://doi.org/10.1002/jbmr.2708.
36. Murphy CM, Schindeler A, Cantrill LC, et al. PTH(1-34) treatment increases bisphosphonate turnover in fracture repair in rats. J Bone Miner Res 2015 30:1022-9.
https://doi.org/10.1002/jbmr.2424.
40. Watts NB, Aggers D, McCarthy EF, et al. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res 2017 32:1027-33.
https://doi.org/10.1002/jbmr.3081.
41. Chiang CY, Zebaze RM, Ghasem-Zadeh A, et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013 52:360-5.
https://doi.org/10.1016/j.bone.2012.10.006.
42. van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical management of patients after atypical femur fractures: a systematic review and recommendations from the european calcified tissue society. J Clin Endocrinol Metab 2020 105:1682-99.
https://doi.org/10.1210/clinem/dgz295.
43. Ha YC, Cho MR, Park KH, et al. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 2010 468:3393-8.
https://doi.org/10.1007/s11999-010-1583-2.
46. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010 95:5258-65.
https://doi.org/10.1210/jc.2010-1571.
47. Prasarn ML, Ahn J, Helfet DL, et al. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res 2012 470:2295-301.
https://doi.org/10.1007/s11999-012-2412-6.
48. Lim HS, Kim CK, Park YS, et al. Factors associated with increased healing time in complete femoral fractures after long-term bisphosphonate therapy. J Bone Joint Surg Am 2016 98:1978-87.
https://doi.org/10.2106/jbjs.15.01422.
49. Lee KJ, Yoo JJ, Oh KJ, et al. Surgical outcome of intramedullary nailing in patients with complete atypical femoral fracture: a multicenter retrospective study. Injury 2017 48:941-5.
https://doi.org/10.1016/j.injury.2017.02.036.
52. Park JH, Lee Y, Shon OJ, et al. Surgical tips of intramedullary nailing in severely bowed femurs in atypical femur fractures: simulation with 3D printed model. Injury 2016 47:1318-24.
https://doi.org/10.1016/j.injury.2016.02.026.
53. Kim JW, Kim H, Oh CW, et al. Surgical outcomes of intramedullary nailing for diaphyseal atypical femur fractures: is it safe to modify a nail entry in bowed femur? Arch Orthop Trauma Surg 2017 137:1515-22.
https://doi.org/10.1007/s00402-017-2764-1.
54. Park YC, Song HK, Zheng XL, et al. Intramedullary nailing for atypical femoral fracture with excessive anterolateral bowing. J Bone Joint Surg Am 2017 99:726-35.
https://doi.org/10.2106/jbjs.16.00760.
55. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010 47:169-80.
https://doi.org/10.1016/j.bone.2010.05.019.
57. Lee YK, Lee YJ, Lee NK, et al. Low positive predictive value of bone scan to predict impending complete fracture among incomplete atypical femoral fracture. J Korean Med Sci 2018 33:e157.
https://doi.org/10.3346/jkms.2018.33.e157.